Therapeutic use of Cannabidiol in dogs: A narrative review
DOI:
https://doi.org/10.33448/rsd-v13i8.46570Keywords:
Cannabinoids; Cannabis sativa; Dogs; Endocannabinoid system.Abstract
Cannabidiol (CBD) is a non-psychotropic phytocannabinoid extract from Cannabis sativa. CBD is increasingly being explored as an alternative to conventional treatments for a e therapeutic role. Several studies support the benefits of CBD such as controlling seizures, acute and chronic pain and decreased pruritus. Other preliminary efficacies point to its role in the inflammatory, immunomodulatory, antiproliferative and associated cell death response. This work aims to carry out a recent and updated bibliographical analysis with reliable scientific evidence related to the mechanisms of action of CBD, including pharmacokinetics, safety, regulation and efficacy in improving pathology in dogs.
References
Anderson, K. L., et al. (2020). Risk factors for canine osteoarthritis and its predisposing arthropathies: A systematic review. Frontiers in Veterinary Science, 7. https://doi.org/10.3389/fvets.2020.00049
Agência Nacional de Vigilância Sanitária. (2022, August 1). Anvisa aprova mais três produtos de Cannabis para uso medicinal. Retrieved from https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/anvisa-aprova-mais-tres-produtos-de-cannabis-para-uso-medicinal. Accessed August 1, 2024.
Barbagallo, S., Finocchiaro, S., & Ahmadi, M. (2018). Veterinary medical use of cannabis, cannabinoid receptors and endocannabinoids system in mammals. The Veterinary Clinics, 48(6), 1087–1102.
Berendt, M., et al. (2015). International veterinary epilepsy task force consensus report on epilepsy definition, classification and terminology in companion animals. BMC Veterinary Research, 11(1).
Brioschi, F. A., et al. (2020). Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: Effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals: An Open Access Journal from MDPI, 10(9), 1505.
Charalambous, M., et al. (2016). Antiepileptic drugs’ tolerability and safety – a systematic review and meta-analysis of adverse effects in dogs. BMC Veterinary Research, 12(1).
Condie, R. M., et al. (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the Murine T-cell line, EL4.IL-2. The Journal of Biological Chemistry, 271(22), 13175–13183.
Corsato Alvarenga, I., et al. (2023). Assessment of cannabidiol use in pets according to a national survey in the USA. The Journal of Small Animal Practice, 64(8), 513–521.
De Andrade, D. F., Gewehr, J. L. H., & De Almeida, E. A. (2022). Safety and efficacy of the therapeutic use of cannabis-based products in the treatment of dogs: An integrative review. Cannabis and Cannabinoid Research, 7(6), 736–744.
Deng, L., et al. (2017). Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. The Journal of Pharmacology and Experimental Therapeutics, 360(1), 215–224.
Di Salvo, A., Conti, M. B., & Della Rocca, G. (2023). Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: An update of current knowledge. Frontiers in Veterinary Science, 10. https://doi.org/10.3389/fvets.2023.1130148
Galve-Roperh, I., et al. (2000). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 6(3), 313–319. https://doi.org/10.1038/73125
Gamble, L.-J., et al. (2018). Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Frontiers in Veterinary Science, 5. https://doi.org/10.3389/fvets.2018.00049
Gray, J. M., et al. (2015). Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. The Journal of Neuroscience, 35(9), 3879–3892. https://doi.org/10.1523/JNEUROSCI.2840-14.2015
Gugliandolo, E., et al. (2021). Effect of cannabidiol (CBD) on canine inflammatory response: An ex vivo study on LPS stimulated whole blood. Veterinary Sciences, 8(9), 185. https://doi.org/10.3390/vetsci8090185
Henry, J. G., et al. (2021). The effect of cannabidiol on canine neoplastic cell proliferation and mitogen‐activated protein kinase activation during autophagy and apoptosis. Veterinary and Comparative Oncology, 19(2), 253–265. https://doi.org/10.1111/vco.12618
Herkenham, M., et al. (1990). Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America, 87(5), 1932–1936. https://doi.org/10.1073/pnas.87.5.1932
Howlett, A. C. (2002). The cannabinoid receptors. Prostaglandins & Other Lipid Mediators, 68–69, 619–631.
Jesudason, D., & Wittert, G. (2008). Endocannabinoid system in food intake and metabolic regulation. Current Opinion in Lipidology, 19(4), 344–348.
Jones, N. A., et al. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics, 332(2), 569–577.
Khasabova, I. A., et al. (2008). A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. The Journal of Neuroscience, 28(44), 11141–11152.
Klein, B. D., et al. (2017). Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP). Neurochemical Research, 42(7), 1939–1948.
Kogan, L., Hellyer, P., & Downing, R. (2020). The use of cannabidiol-rich hemp oil extract to treat canine osteoarthritis-related pain: A pilot study. AHVMA Journal, 58.
Landa, L., Sulcova, A., & Gbelec, P. (2016). The use of cannabinoids in animals and therapeutic implications for veterinary medicine: A review. Veterinarni Medicina, 61(3), 111–122.
Łebkowska-Wieruszewska, B., et al. (2019). Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. Research in Veterinary Science, 123, 26–28.
Loewinger, M., et al. (2022). The effect of a mixed cannabidiol and cannabidiolic acid based oil on client‐owned dogs with atopic dermatitis. Veterinary Dermatology, 33(4), 329.
Mackie, K. (2008). Cannabinoid receptors: Where they are and what they do. Journal of Neuroendocrinology, 20(s1), 10–14.
Marcu, J. P., Christian, R. T., Lau, D., Zielinski, A. J., Horowitz, M. P., Lee, J., Pakdel, A., Allison, J., & Limbad, C. (2010). Cannabidiol enhances the inhibitory effects of Δ9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Molecular Cancer Therapeutics, 9(1), 180–189.
Mariga, C., Verbruggen, E., Vanhaecke, L., Paepe, D., Daminet, S., & Hesta, M. (2023). Dermatological evaluation in dogs with atopic dermatitis treated with full-spectrum high cannabidiol oil: A pre study part 1. Frontiers in Veterinary Science, 10.
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 346(6284), 561–564.
McGrath, S., Bartner, L. R., Rao, S., Packer, R. A., & Gustafson, D. L. (2019). Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association, 254(11), 1301–1308.
Monteiro, B. P., Dycus, D. L., Duarte, J. D., Kieves, N. R., & Steagall, P. V. (2023). 2022 WSAVA guidelines for the recognition, assessment and treatment of pain. The Journal of Small Animal Practice, 64(4), 177–254.
Monteiro-Steagall, B. P., Steagall, P. V. M., & Lascelles, B. D. X. (2013). Systematic review of nonsteroidal anti‐inflammatory drug‐induced adverse effects in dogs. Journal of Veterinary Internal Medicine, 27(5), 1011–1019.
Muñana, K. R. (2013). Management of refractory epilepsy. Topics in Companion Animal Medicine, 28(2), 67–71.
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature, 365(6441), 61–65.
Nakajima, Y., Furuichi, Y., Biswas, K. K., Hashiguchi, T., Kawahara, K., Yamaji, K., Uchimura, T., Izumi, Y., Maruyama, I., & Tancharoen, S. (2006). Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF‐κB pathway inhibition. FEBS Letters, 580(2), 613–619.
Nuttall, T., Uri, M., & Halliwell, R. (2013). Canine atopic dermatitis – What have we learned? The Veterinary Record, 172(8), 201–207.
Obafemi, A. I., Vearrier, D., Goodloe, J. M., & Weachter, R. (2015). Cluster of acute toxicity from ingestion of synthetic cannabinoid-laced brownies. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, 11(4), 426–429.
Patikorn, C., Appleyard, C. B., Melendez, M., & Leamy, K. A. (2023). Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: A systematic review and meta-analysis of animal intervention studies. Frontiers in Veterinary Science, 10.
Pertwee, R. G. (2000). Cannabinoid receptor ligands: Clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opinion on Investigational Drugs, 9(7), 1553–1571.
Pertwee, R. G. (2001). Cannabinoid receptors and pain. Progress in Neurobiology, 63(5), 569–611.
Pettitt, R. A., & German, A. J. (2015). Investigation and management of canine osteoarthritis. In Practice, 37(S1), 1–8.
Powles, T., te Poele, R., Shamash, J., Chaplin, T., Propper, D., Joel, S., Oliver, T., & Liu, W. M. (2005). Cannabis-induced cytotoxicity in leukemic cell lines: The role of the cannabinoid receptors and the MAPK pathway. Blood, 105(3), 1214–1221.
Rozental, A. J., Monteiro, B. P., Bordas, E., White, R. S., & Steagall, P. V. M. (2023). The efficacy and safety of cannabidiol as adjunct treatment for drug‐resistant idiopathic epilepsy in 51 dogs: A double‐blinded crossover study. Journal of Veterinary Internal Medicine, 37(6), 2291–2300.
Samara, E., Bialer, M., & Mechoulam, R. (1988). Pharmacokinetics of cannabidiol in dogs. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 16(3), 469–472.
Scott, K. A., Dalgleish, A. G., & Liu, W. M. (2014). The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Molecular Cancer Therapeutics, 13(12), 2955–2967.
Shilo-Benjamini, Y., Buskila, Y., Tahiroglu, M., Benjamin, S., & Schachor, T. (2023). Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: A pilot clinical study in dogs with naturally-occurring osteoarthritis. Frontiers in Veterinary Science, 10.
Silver, R. J. (2019). The endocannabinoid system of animals. Animals: An Open Access Journal from MDPI, 9(9), 686.
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019). Use of cannabidiol in the treatment of epilepsy: Efficacy and security in clinical trials. Molecules (Basel, Switzerland), 24(8), 1459.
Sulcova, E. (1998). Biphasic effects of anandamide. Pharmacology, Biochemistry, and Behavior, 59(2), 347–352.
Sultan, A. S., Marie, M. A., & Sheweita, S. A. (2018). Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. Breast (Edinburgh, Scotland), 41, 34–41.
Verrico, C. D., Wesson, S., Kondela, K. N., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Dunner, K., & Decker, W. K. (2020). A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain, 161(9), 2191–2202.
Wessmann, A., Volk, H. A., Parkin, T., & Ortega, M. (2014). Evaluation of quality of life in dogs with idiopathic epilepsy. Journal of Veterinary Internal Medicine, 28(2), 510–514.
Yu, C. H. J., & Rupasinghe, H. P. V. (2021). Cannabidiol-based natural health products for companion animals: Recent advances in the management of anxiety, pain, and inflammation. Research in Veterinary Science, 140, 38–46
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jéssica Guimarães Braga; Letícia Abreu Caresia; Bruna Rezende Chaves
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
